Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Aditya K. Gupta, Sarah G. Versteeg & Neil H. Shear. (2018) Common drug-drug interactions in antifungal treatments for superficial fungal infections. Expert Opinion on Drug Metabolism & Toxicology 14:4, pages 387-398.
Read now
Read now
Anastazia A. Kei, Theodosios D. Filippatos & Moses S. Elisaf. (2016) The safety of ezetimibe and simvastatin combination for the treatment of hypercholesterolemia. Expert Opinion on Drug Safety 15:4, pages 559-569.
Read now
Read now
Theodosios D Filippatos & Moses S Elisaf. (2015) Safety considerations with fenofibrate/simvastatin combination. Expert Opinion on Drug Safety 14:9, pages 1481-1493.
Read now
Read now
Pauline L Jacinto & Pranatharthi Chandrasekar. (2013) Safety of posaconazole
. Expert Opinion on Drug Safety 12:2, pages 265-274.
Read now
Read now
Articles from other publishers (28)
Aleksi M. Olkkola, Tuija Tapaninen, Aleksi Tornio, Milka Hauta‐aho, Outi Lapatto‐Reiniluoto, Mikko Neuvonen, Johanna I. Kiiski, Pertti J. Neuvonen, Mikko Niemi & Janne T. Backman. (2023) Posaconazole‐ibrutinib interaction cannot be avoided by staggered dosing: How to optimize ibrutinib dose during posaconazole treatment. British Journal of Clinical Pharmacology.
Crossref
Crossref
Erik Hahn, Renae Chavira, Lance Wollenberg, Weiwei Tan & Micaela B. Reddy. (2023) Impact of posaconazole and diltiazem on pharmacokinetics of encorafenib, a BRAF V600 kinase inhibitor for melanoma and colorectal cancer with BRAF mutations. Clinical and Translational Science.
Crossref
Crossref
Ji Dong, Shuai-bing Liu, Jony Md Rasheduzzaman, Chen-rong Huang & Li-yan Miao. (2022) Development of Physiology Based Pharmacokinetic Model to Predict the Drug Interactions of Voriconazole and Venetoclax. Pharmaceutical Research 39:8, pages 1921-1933.
Crossref
Crossref
Eric D. Eisenmann, Dominique A. Garrison, Zahra Talebi, Yan Jin, Josie A. Silvaroli, Jin-Gyu Kim, Alex Sparreboom, Michael R. Savona, Alice S. Mims & Sharyn D. Baker. (2022) Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax Elimination. Pharmaceutics 14:4, pages 694.
Crossref
Crossref
Sumit Bhatnagar, Dwaipayan Mukherjee, Ahmed Hamed Salem, Dale Miles, Rajeev M. Menon & John P. Gibbs. (2021) Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug–drug interaction predictions using a PBPK approach. Cancer Chemotherapy and Pharmacology 87:4, pages 465-474.
Crossref
Crossref
Brit Silja Rohr & Gerd Mikus. (2020) Proposal of a Safe and Effective Study Design for CYP3A‐Mediated Drug‐Drug Interactions. The Journal of Clinical Pharmacology 60:10, pages 1294-1303.
Crossref
Crossref
Krishna K. Machavaram, Chihiro Endo-Tsukude, Kimio Terao, Katherine L. Gill, Oliver J. Hatley, Iain Gardner, Neil Parrott & Patricia Sanwald Ducray. (2019) Simulating the Impact of Elevated Levels of Interleukin-6 on the Pharmacokinetics of Various CYP450 Substrates in Patients with Neuromyelitis Optica or Neuromyelitis Optica Spectrum Disorders in Different Ethnic Populations. The AAPS Journal 21:3.
Crossref
Crossref
Christina R. Chow, Jerold S. Harmatz, Michael J. Ryan & David J. Greenblatt. (2018) Persistence of a Posaconazole-Mediated Drug-Drug Interaction With Ranolazine After Cessation of Posaconazole Administration: Impact of Obesity and Implications for Patient Safety. The Journal of Clinical Pharmacology 58:11, pages 1436-1442.
Crossref
Crossref
Yumi Cleary, Michael Gertz, Peter N. Morcos, Li Yu, Kuresh Youdim, Alex Phipps, Stephen Fowler & Neil Parrott. (2018) Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development. Clinical Pharmacology & Therapeutics 104:3, pages 505-514.
Crossref
Crossref
David J. Greenblatt, Jerold S. Harmatz, Michael J. Ryan & Christina R. Chow. (2018) Sustained Impairment of Lurasidone Clearance After Discontinuation of Posaconazole. Journal of Clinical Psychopharmacology 38:4, pages 289-295.
Crossref
Crossref
Felix Stader, Hannah Kinvig, Manuel Battegay, Saye Khoo, Andrew Owen, Marco Siccardi & Catia Marzolini. (2018) Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications. Antimicrobial Agents and Chemotherapy 62:7.
Crossref
Crossref
David E. Coutant & Stephen D. Hall. (2018) Disease-Drug Interactions in Inflammatory States via Effects on CYP-Mediated Drug Clearance. The Journal of Clinical Pharmacology 58:7, pages 849-863.
Crossref
Crossref
Jarrett R. Amsden & Paul O. Gubbins. 2018. Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions. Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions
425
501
.
Leigh Anne Hylton Gravatt, Rachel W. Flurie, Estela Lajthia & Dave L. Dixon. (2017) Clinical Guidance for Managing Statin and Antimicrobial Drug-Drug Interactions. Current Atherosclerosis Reports 19:11.
Crossref
Crossref
Andreas H. Groll, Robert Townsend, Amit Desai, Nkechi Azie, Mark Jones, Marc Engelhardt, Anne-Hortense Schmitt-Hoffman & Roger J. M. Brüggemann. (2017) Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4. Transplant Infectious Disease 19:5, pages e12751.
Crossref
Crossref
Michael B. Bottorff, David R. Bright & David F. Kisor. (2017) Commentary: Should Pharmacogenomic Evidence Be Considered in Clinical Decision Making? Focus on Select Cardiovascular Drugs. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 37:9, pages 1005-1013.
Crossref
Crossref
Peter N. Morcos, Yumi Cleary, Elena Guerini, Georgina Dall, Katrijn Bogman, Luigi De Petris, Santiago Viteri, Walter Bordogna, Li Yu, Meret Martin-Facklam & Alex Phipps. (2017) Clinical Drug-Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib. Clinical Pharmacology in Drug Development 6:3, pages 280-291.
Crossref
Crossref
Holger Petri. (2017) Arzneimitteltherapiesicherheit: Interaktionspotenzial der Azol-Antimykotika. Deutsches Ärzteblatt Online.
Crossref
Crossref
Lichuan Liu, Akintunde Bello, Mark J. Dresser, Donald Heald, Steven Ferenc Komjathy, Edward O'Mara, Mark Rogge, S. Aubrey Stoch & Sarah M. Robertson. (2016) Best practices for the use of itraconazole as a replacement for ketoconazole in drug-drug interaction studies. The Journal of Clinical Pharmacology 56:2, pages 143-151.
Crossref
Crossref
Simon Leung, Mara Poulakos & Jade Machin. (2015) Posaconazole: An Update of Its Clinical Use. Pharmacy 3:4, pages 210-268.
Crossref
Crossref
Anne Poon & Lowan K. Ly. 2015. Thomas’ Hematopoietic Cell Transplantation. Thomas’ Hematopoietic Cell Transplantation
1206
1217
.
Santiago Vilar, Tal Lorberbaum, George Hripcsak & Nicholas P. Tatonetti. (2015) Improving Detection of Arrhythmia Drug-Drug Interactions in Pharmacovigilance Data through the Implementation of Similarity-Based Modeling. PLOS ONE 10:6, pages e0129974.
Crossref
Crossref
Anthony J. Guarascio & Douglas Slain. (2015) Review of the New Delayed-Release Oral Tablet and Intravenous Dosage Forms of Posaconazole. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 35:2, pages 208-219.
Crossref
Crossref
M. M. Chau, D. C. M. Kong, S. J. van Hal, K. Urbancic, J. A. Trubiano, M. Cassumbhoy, J. Wilkes, C. M. Cooper, J. A. Roberts, D. J. E. Marriott & L. J. Worth. (2014) Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014. Internal Medicine Journal 44:12b, pages 1364-1388.
Crossref
Crossref
Constance Loue & Michel Tod. (2014) Reliability and Extension of Quantitative Prediction of CYP3A4-Mediated Drug Interactions Based on Clinical Data. The AAPS Journal 16:6, pages 1309-1320.
Crossref
Crossref
Jasper Dingemanse, Hans Gabriel Cruz, Martine Gehin & Petra Hoever. (2014) Pharmacokinetic Interactions Between the Orexin Receptor Antagonist Almorexant and the CYP3A4 Inhibitors Ketoconazole and Diltiazem. Journal of Pharmaceutical Sciences 103:5, pages 1548-1556.
Crossref
Crossref
R. Benigni, C. L. Battistelli, C. Bossa, O. Tcheremenskaia & P. Crettaz. (2013) New perspectives in toxicological information management, and the role of ISSTOX databases in assessing chemical mutagenicity and carcinogenicity. Mutagenesis 28:4, pages 401-409.
Crossref
Crossref
Antonio Ruggiero, Roberta Arena, Andrea Battista, Daniela Rizzo, Giorgio Attinà & Riccardo Riccardi. (2012) Azole interactions with multidrug therapy in pediatric oncology. European Journal of Clinical Pharmacology 69:1, pages 1-10.
Crossref
Crossref